Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Tables)

v3.22.2.2
NET LOSS PER SHARE (Tables)
9 Months Ended
Sep. 30, 2022
NET LOSS PER SHARE  
Schedule of antidilutive securities excluded from computation of earnings per share

As of September 30, 

    

2022

    

2021

Warrants

 

1,563,381

 

1,607,961

Preferred shares as convertible into common stock

 

111,111

 

694,444

Stock options

 

654,263

 

470,178

Total potentially dilutive shares

 

2,328,755

 

2,772,583